IL274837B2 - Combination therapy for cancer treatment - Google Patents

Combination therapy for cancer treatment

Info

Publication number
IL274837B2
IL274837B2 IL274837A IL27483720A IL274837B2 IL 274837 B2 IL274837 B2 IL 274837B2 IL 274837 A IL274837 A IL 274837A IL 27483720 A IL27483720 A IL 27483720A IL 274837 B2 IL274837 B2 IL 274837B2
Authority
IL
Israel
Prior art keywords
cells
fetal
combination
use according
carcinoma
Prior art date
Application number
IL274837A
Other languages
English (en)
Hebrew (he)
Other versions
IL274837A (en
IL274837B1 (en
Original Assignee
Inst Nat Sante Rech Med
Hopitaux Paris Assist Publique
Univ Paris Saclay
Univ Paris Cite
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Hopitaux Paris Assist Publique, Univ Paris Saclay, Univ Paris Cite filed Critical Inst Nat Sante Rech Med
Publication of IL274837A publication Critical patent/IL274837A/en
Publication of IL274837B1 publication Critical patent/IL274837B1/en
Publication of IL274837B2 publication Critical patent/IL274837B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/54—Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IL274837A 2017-11-24 2018-11-23 Combination therapy for cancer treatment IL274837B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17306635 2017-11-24
PCT/EP2018/082429 WO2019101956A1 (en) 2017-11-24 2018-11-23 Methods and compositions for treating cancers

Publications (3)

Publication Number Publication Date
IL274837A IL274837A (en) 2020-07-30
IL274837B1 IL274837B1 (en) 2024-09-01
IL274837B2 true IL274837B2 (en) 2025-01-01

Family

ID=60627577

Family Applications (2)

Application Number Title Priority Date Filing Date
IL274837A IL274837B2 (en) 2017-11-24 2018-11-23 Combination therapy for cancer treatment
IL314506A IL314506A (en) 2017-11-24 2018-11-23 Methods and preparations for the treatment of cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL314506A IL314506A (en) 2017-11-24 2018-11-23 Methods and preparations for the treatment of cancer

Country Status (9)

Country Link
US (2) US11679148B2 (https=)
EP (1) EP3713596A1 (https=)
JP (3) JP7408036B2 (https=)
KR (2) KR20250008153A (https=)
CN (1) CN111670043A (https=)
AU (2) AU2018371212B2 (https=)
CA (1) CA3083158A1 (https=)
IL (2) IL274837B2 (https=)
WO (1) WO2019101956A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
WO2015105955A1 (en) 2014-01-08 2015-07-16 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
WO2020030634A1 (en) 2018-08-06 2020-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating cancers
US20220313734A1 (en) * 2019-05-09 2022-10-06 Figene, Llc Fibroblast generated patient-specific vaccines
CN110609141A (zh) * 2019-09-30 2019-12-24 中山大学孙逸仙纪念医院 Gltscr1前列腺癌预后检测试剂及其试剂盒
CN113061656A (zh) * 2021-03-25 2021-07-02 南京先声医学检验有限公司 Tet1基因突变在预测结肠癌患者对免疫检查点抑制剂疗法敏感性中的应用
CN113144181B (zh) * 2021-04-20 2022-07-19 徐州医科大学 一种靶向b7h3的dna疫苗、制备方法及应用
US20220347349A1 (en) * 2021-04-30 2022-11-03 Stemcellago Inc. Engineered cartilage
CN114774359B (zh) * 2022-03-24 2022-11-08 中山大学附属第一医院 一种宫颈鳞癌类器官培养基及其构建方法
CN116859049A (zh) * 2023-04-20 2023-10-10 中国科学院基础医学与肿瘤研究所(筹) 用于结直肠癌诊断的肿瘤标志物及基于核酸适体的检测方法
CN120384042B (zh) * 2024-01-29 2025-11-28 北京大学第一医院(北京大学第一临床医学院) 一种优化人多潜能干细胞来源肾脏类器官的重组蛋白制剂
CN120966999B (zh) * 2025-10-22 2026-01-09 宁波大学 Klhl14基因在制备结肠癌、5-fu耐受结肠癌诊断试剂中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012122629A1 (en) * 2011-03-11 2012-09-20 Mcmaster University A method of vaccination comprising a histone deacetylase inhibitor

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8200523A (nl) 1982-02-11 1983-09-01 Univ Leiden Werkwijze voor het in vitro transformeren van planteprotoplasten met plasmide-dna.
US4806476A (en) 1983-09-08 1989-02-21 Lovelace Medical Foundation Efficient cell fusion process
US5071773A (en) 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
JP2740320B2 (ja) 1988-08-04 1998-04-15 アムラド・コーポレイション・リミテッド 胚幹細胞のインビトロ増殖
US5240840A (en) 1991-04-05 1993-08-31 Regents Of The University Of Michigan Dna superfragment cloning
US5637483A (en) 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
JP3314241B2 (ja) 1992-04-06 2002-08-12 ヤマハ発動機株式会社 自動二輪車用エンジンの排気浄化装置
US5453357A (en) 1992-10-08 1995-09-26 Vanderbilt University Pluripotential embryonic stem cells and methods of making same
US5690926A (en) 1992-10-08 1997-11-25 Vanderbilt University Pluripotential embryonic cells and methods of making same
US5618829A (en) 1993-01-28 1997-04-08 Mitsubishi Chemical Corporation Tyrosine kinase inhibitors and benzoylacrylamide derivatives
AU691820B2 (en) 1993-07-15 1998-05-28 Cancer Research Campaign Technology Limited Prodrugs of protein tyrosine kinase inhibitors
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
US5914268A (en) 1994-11-21 1999-06-22 National Jewish Center For Immunology & Respiratory Medicine Embryonic cell populations and methods to isolate such populations
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US5639757A (en) 1995-05-23 1997-06-17 Pfizer Inc. 4-aminopyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
HU228446B1 (en) 1996-04-12 2013-03-28 Warner Lambert Co Kinazoline derivatives as irreversible inhibitors of protein-kinase, pharmaceutical compositions containing these compounds and use thereof
US6207157B1 (en) 1996-04-23 2001-03-27 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for nontypeable Haemophilus influenzae
US6331406B1 (en) 1997-03-31 2001-12-18 The John Hopkins University School Of Medicine Human enbryonic germ cell and methods of use
US6090622A (en) 1997-03-31 2000-07-18 The Johns Hopkins School Of Medicine Human embryonic pluripotent germ cells
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
US6100254A (en) 1997-10-10 2000-08-08 Board Of Regents, The University Of Texas System Inhibitors of protein tyrosine kinases
AU729377B2 (en) 1997-10-23 2001-02-01 Asterias Biotherapeutics, Inc. Methods and materials for the growth of primate-derived primordial stem cells in feeder-free culture
US6667176B1 (en) 2000-01-11 2003-12-23 Geron Corporation cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US6740665B1 (en) 1999-02-10 2004-05-25 Ramachandran Murali Tyrosine kinase inhibitors and methods of using the same
US6245759B1 (en) 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
AU5636900A (en) 1999-06-30 2001-01-31 Merck & Co., Inc. Src kinase inhibitor compounds
JP2003503351A (ja) 1999-06-30 2003-01-28 メルク エンド カムパニー インコーポレーテッド Ｓｒｃキナーゼ阻害化合物
WO2001000214A1 (en) 1999-06-30 2001-01-04 Merck & Co., Inc. Src kinase inhibitor compounds
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
IL148079A0 (en) 1999-08-24 2002-09-12 Medarex Inc Human ctla-4 antibodies and compositions containing the same
DE60023926T2 (de) 1999-09-10 2006-07-20 Merck & Co., Inc. Tyrosin kinase inhibitoren
AU778042B2 (en) 1999-10-19 2004-11-11 Merck & Co., Inc. Tyrosine kinase inhibitors
US6794393B1 (en) 1999-10-19 2004-09-21 Merck & Co., Inc. Tyrosine kinase inhibitors
HRP20020349A2 (en) 1999-10-19 2004-02-29 Merck & Co Inc Tyrosine kinase inhibitors
US6313138B1 (en) 2000-02-25 2001-11-06 Merck & Co., Inc. Tyrosine kinase inhibitors
US6420382B2 (en) 2000-02-25 2002-07-16 Merck & Co., Inc. Tyrosine kinase inhibitors
NL1017973C2 (nl) 2000-05-10 2002-11-08 Tristem Trading Cyprus Ltd Inrichting.
WO2002018549A1 (en) 2000-08-30 2002-03-07 Maria Biotech Co., Ltd. Human embryonic stem cells derived from frozen-thawed embryo
JP4183614B2 (ja) 2001-05-31 2008-11-19 伸弥 山中 Ｅｓ細胞特異的発現遺伝子
ATE316088T1 (de) 2001-06-22 2006-02-15 Merck & Co Inc Tyrosin-kinase inhibitoren
WO2003011836A1 (en) 2001-08-01 2003-02-13 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003020276A1 (en) 2001-08-30 2003-03-13 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003042402A2 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
US7951592B2 (en) 2003-11-10 2011-05-31 The Scripps Research Institute Compositions and methods for inducing cell dedifferentiation
RU2494107C2 (ru) 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
US8129187B2 (en) 2005-12-13 2012-03-06 Kyoto University Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2
US8278104B2 (en) 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
US7908091B2 (en) 2006-03-17 2011-03-15 Prometheus Laboratories Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
HRP20131167T1 (hr) 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. Antitijela za humani receptor programirane smrti pd-1
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
SG10201400329YA (en) 2008-05-02 2014-05-29 Univ Kyoto Method of nuclear reprogramming
KR101814408B1 (ko) 2008-09-26 2018-01-04 다나-파버 캔서 인스티튜트 인크. 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
WO2010089411A2 (en) 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
WO2011082400A2 (en) 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
CN102906249A (zh) * 2010-05-25 2013-01-30 独立行政法人国立癌症研究中心 能够在体外自我复制的诱导性前癌干细胞或诱导性恶性干细胞，这些细胞的制备方法，及这些细胞的应用
JP2013532153A (ja) 2010-06-18 2013-08-15 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
JP5888753B2 (ja) 2010-11-04 2016-03-22 国立大学法人京都大学 効率的な人工多能性幹細胞の樹立方法
US20130136722A1 (en) 2011-11-11 2013-05-30 The Board Of Trustees Of The University Of Illinois Methods of Ex Vivo Expansion of Blood Progenitor Cells, and Generation of Composite Grafts
KR101467631B1 (ko) * 2012-05-22 2014-12-05 가톨릭대학교 산학협력단 자살 유전자 치료법에서의 발프로산의 기능
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
BR112017008399A2 (pt) 2014-10-24 2018-06-19 StemImmune, Incorporated abordagem de imunoterapia de combinação para tratamento de câncer
AU2014277667B2 (en) * 2014-12-15 2022-07-14 The University Of Queensland Differentiation of pluripotent stem cells to form renal organoids
HK1248588A1 (zh) 2015-08-11 2018-10-19 Calidi Biotherapeutics, Inc. 用於癌症治疗中的天花疫苗
CN109689089A (zh) 2016-05-25 2019-04-26 国家医疗保健研究所 治疗癌症的方法和组合物
US20180296850A1 (en) 2017-04-14 2018-10-18 Tianxin Wang Reagents and methods for cancer treatment using Magnetic particle

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012122629A1 (en) * 2011-03-11 2012-09-20 Mcmaster University A method of vaccination comprising a histone deacetylase inhibitor

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BYRAM W BRIDLE ET AL:, HDAC INHIBITION SUPPRESSES PRIMARY IMMUNE RESPONSES, ENHANCES SECONDARY IMMUNE RESPONSES, AND ABROGATES AUTOIMMUNITY DURING TUMOR IMMUNOTHERAPY, 8 January 2013 (2013-01-08) *
DAVID L BARTLETT ET AL:, ONCOLYTIC VIRUSES AS THERAPEUTIC CANCER VACCINES, 11 September 2013 (2013-09-11) *
DI WU ET AL:, EFFECT OF TARGETED OVARIAN CANCER IMMUNOTHERAPY USING OVARIAN CANCER STEM CELL VACCINE, 24 October 2015 (2015-10-24) *
LAI M-D ET AL:, AN HDAC INHIBITOR ENHANCES THE ANTITUMOR ACTIVITY OF A CMV PROMOTER-DRIVEN DNA VACCINE., 31 March 2010 (2010-03-31) *
LI SHEN ET AL:, CLASS I HISTONE DEACETYLASE INHIBITOR ENTINOSTAT SUPPRESSES REGULATORY T CELLS AND ENHANCES IMMUNOTHERAPIES IN RENAL AND PROSTATE CANCER MODELS, 27 January 2012 (2012-01-27) *
LISIERO DOMINIQUE N ET AL:, THE HISTONE DEACETYLASE INHIBITOR, LBH589, PROMOTES THE SYSTEMIC CYTOKINE AND EFFECTOR RESPONSES OF ADOPTIVELY TRANSFERRED CD8+ T CELLS., 31 December 2014 (2014-12-31) *
ZHENG QI ET AL,, A HEPATIC STEM CELL VACCINE IS SUPERIOR TO AN EMBRYONIC STEM CELL VACCINE IN THE PROPHYLAXIS AND TREATMENT OF MURINE HEPATOCARCINOMA, 31 March 2017 (2017-03-31) *

Also Published As

Publication number Publication date
IL274837A (en) 2020-07-30
JP2024000006A (ja) 2024-01-04
JP2026016542A (ja) 2026-02-03
KR20200111168A (ko) 2020-09-28
JP7408036B2 (ja) 2024-01-05
EP3713596A1 (en) 2020-09-30
US20210030855A1 (en) 2021-02-04
KR102752418B1 (ko) 2025-01-10
IL274837B1 (en) 2024-09-01
US12403110B2 (en) 2025-09-02
US11679148B2 (en) 2023-06-20
AU2025205174A1 (en) 2025-07-24
WO2019101956A1 (en) 2019-05-31
JP2021504465A (ja) 2021-02-15
IL314506A (en) 2024-09-01
CN111670043A (zh) 2020-09-15
CA3083158A1 (en) 2019-05-31
AU2018371212B2 (en) 2025-04-17
AU2018371212A1 (en) 2020-06-11
US20230338494A1 (en) 2023-10-26
KR20250008153A (ko) 2025-01-14

Similar Documents

Publication Publication Date Title
IL274837B2 (en) Combination therapy for cancer treatment
US12241090B2 (en) Methods and systems for converting precursor cells into gastric tissues through directed differentiation
JP7160855B2 (ja) 多能性細胞の誘導法
AU2023202507B2 (en) Cell compositions derived from dedifferentiated reprogrammed cells
JP2021504465A5 (https=)
CA2747398A1 (en) Generation and maintenance of stem cells
JP2023511408A (ja) ヒト多能性幹細胞からのストロマフリーｔ細胞分化法
US11773387B2 (en) Device and method for inducing pluripotent cells using energy
Han et al. Induced pluripotent stem cells: emerging techniques for nuclear reprogramming
US20130059385A1 (en) Methods of generating pluripotent stem cells
Sun et al. Induced pluripotent cancer cells: progress and application
JP2025535084A (ja) Ｔ細胞分化のための方法及び組成物
HK40057032B (zh) 用於经由定向分化将前体细胞转化为胃组织的方法和系统
Chung Manipulating Somatic Cells to Remove Barriers in Induced Pluripotent Stem Cell Reprogramming
HK40037443A (en) Methods and systems for converting precursor cells into gastric tissues through directed differentiation
Hui Hu He et al. Small Molecule-induced Beta-cell Regeneration from Alternate Cell Sources
Han et al. 3 Induced Pluripotent
DiLabio Reprogramming Mouse Glioma Stem Cells with Defined Factors